Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501704 | 0.86 | SCN9A (0.36) | SCN9AKDM4DEDNRASCN7ASCN5A | |
| SCHEMBL502331 | 0.78 | SCN9A (0.36) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281917 | 0.76 | TP53 (0.39) | SCN9ALMNA | |
| SCHEMBL280862 | 0.74 | SCN9A (0.47) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL484076 | 0.70 | SCN9A (0.43) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL483976 | 0.69 | SCN9A (0.38) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280901 | 0.69 | SCN9A (0.67) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL14221689 | 0.68 | SCN9A (0.37) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL14221699 | 0.67 | SCN9A (0.36) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10258994 | 0.67 | GPR119 (0.39) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |